tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Artificial Pancreas'

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Written by Ι Stock Market Media — February 8, 2016

Johnson & Johnson, like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, Johnson & Johnson’s head of global innovation, said that his company’s recent decision to partner with a privately held San Diego biotech was to “hedge our bets to make sure we would win in this space.” Johnson & Johnson’s deal with ViaCyte, Inc. is an effort to ...

Read More →
0

Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment with License for Insulin-Producing Cells

Written by Ι Stock Market Media Group Staff — October 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology.  It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.

Now, almost ...

Read More →
0

Investors Confidently Back Nuvilex’s Acquisition of Diabetes Technology

Investors Confidently Back Nuvilex’s Acquisition of Diabetes Technology

Written by ι Stock Market Media Group Staff — November 12, 2013

Nuvilex, Inc. (OTCQB: NVLX) announced last week that it has acquired the exclusive worldwide rights to a cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  In order to pull off the acquisition, Nuvilex had to convince investors to part with $1.5 million dollars in cash.  One wouldn’t think this a hard sell given the acquisition could lead to a multi-billion dollar treatment for the company.  And, you’d ...

Read More →
0

Nuvilex, Inc. ι Diabetes Studies Could Eliminate Need for Daily Insulin Requirements

Nuvilex, Inc. ι Diabetes Studies Could Eliminate Need for Daily Insulin Requirements

Written by ι Stock Market Media Staff — March 18, 2013

When investors look into biotechnology and pharmaceutical companies as an investment opportunity, three areas of research stand out as the most favorable for future returns.  The big three are cancer, heart disease and diabetes research that can eventually lead to corresponding clinical trials.  Well, Nuvilex, Inc. (OTCQB: NVLX) is currently involved in 2 of the 3 – cancer and diabetes.

While Nuvilex prepares for a large-scale, late-phase clinical ...

Read More →
0

Nuvilex, Inc. Expects its Technology Can Start to Change Life for Diabetics

Nuvilex, Inc. Expects its Technology Can Start to Change Life for Diabetics

Written by ι Stock Market Media — April 8, 2013

When Nuvilex, Inc. (OTCQB: NVLX) started its diabetes studies, it was likely well known then that while its late-stage pancreatic cancer trials are front and center, it is the company’s work in diabetes that could put it on the map and really turn some heads.  The small Silver Spring, Maryland, biotechnology company is already getting attention for its cell encapsulation technology’s performance in its preclinical diabetes studies, and ...

Read More →
0
ContactUs.com